Essex Investment Management Co. LLC Has $472,000 Holdings in Spark Therapeutics, Inc. (ONCE)

Essex Investment Management Co. LLC cut its position in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 51.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,298 shares of the biotechnology company’s stock after selling 5,536 shares during the period. Essex Investment Management Co. LLC’s holdings in Spark Therapeutics were worth $472,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ONCE. Ameritas Investment Partners Inc. raised its stake in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics during the second quarter worth about $143,000. BNP Paribas Arbitrage SA raised its stake in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. raised its stake in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new position in Spark Therapeutics during the first quarter worth about $227,000. 77.30% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Essex Investment Management Co. LLC Has $472,000 Holdings in Spark Therapeutics, Inc. (ONCE)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/06/essex-investment-management-co-llc-has-472000-holdings-in-spark-therapeutics-inc-once.html.

Spark Therapeutics, Inc. (ONCE) opened at $82.06 on Monday. Spark Therapeutics, Inc. has a twelve month low of $39.90 and a twelve month high of $91.75.

In other news, CEO Jeffrey D. Marrazzo sold 15,000 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $75.10, for a total value of $1,126,500.00. Following the completion of the transaction, the chief executive officer now owns 245,000 shares in the company, valued at approximately $18,399,500. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $81.00, for a total transaction of $445,500.00. Following the completion of the transaction, the insider now owns 10,825 shares of the company’s stock, valued at approximately $876,825. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,090,850 shares of company stock valued at $91,901,774. Company insiders own 7.30% of the company’s stock.

A number of research firms have recently issued reports on ONCE. UBS AG reissued a “buy” rating and issued a $92.00 price target (up from $70.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Jefferies Group LLC began coverage on shares of Spark Therapeutics in a research note on Monday, July 10th. They issued a “buy” rating and a $85.00 price target on the stock. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $60.00 to $100.00 in a research note on Wednesday, August 2nd. Cantor Fitzgerald set a $94.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $92.00 price target (up from $77.00) on shares of Spark Therapeutics in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. Spark Therapeutics currently has an average rating of “Buy” and a consensus target price of $90.47.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics, Inc. (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

What are top analysts saying about Spark Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Spark Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit